India's Laurus Labs rises on approval for COVID-19 drug 2-DG

Laurus Labs

02/07/2021 08:41

** Shares of Indian generic drugmaker  LAUL.NS  gain as much
as 3.5% to 689.85 rupees
    ** LAUL gets license from India's defence research agency to
make and sell COVID-19 drug 2-Deoxy-D-Glucose, known as 2-DG
 urn:newsml:reuters.com:*:nFWN2OD146
    ** 2-DG was developed by the Defence Research and
Development Organisation's (DRDO) Institute of Nuclear Medicine
and Allied Sciences in collaboration with Dr Reddy's
Laboratories  REDY.NS , and was given https://bit.ly/3zQVnP3
emergency-use approval in early May
    ** On Monday, REDY announced the commercial launch of 2-DG
at a maximum retail price of 990 rupees ($13.24) per sachet
 urn:newsml:reuters.com:*:nFWN2O900L
    ** Last week, another drugmaker Shilpa Medicare  SHME.NS 
got in-principle approval from DRDO to make and sell 2-DG
 urn:newsml:reuters.com:*:nFWN2O60OU   
    ** Up to Thursday's close, LAUL stock up 88.7% this year
    


($1 = 74.7950 Indian rupees)

 (Reporting by Anuron Kumar Mitra in Bengaluru)
 ((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))